Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

NCT01672853 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sclerosing Cholangitis (PSC)

Interventions

BIOLOGICAL: Simtuzumab
BIOLOGICAL: Placebo

Sponsor

Gilead Sciences